Trial Profile

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Granulocyte macrophage colony stimulating factor
Indications Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms PROSPECT
Sponsors Bavarian Nordic; BN ImmunoTherapeutics

06 Apr 2022 This trial has been completed in Netherland (End Date: 02 Oct 2017), according to European Clinical Trials Database record.
28 Feb 2019 Argentina,Austria, Brazil, Chile, Czech Republic,Lithuania, Mexico, Panama, Slovakia, Switzerland, were the planned locations as per European Clinical Trials Database record.
28 Feb 2019 Results assessing median overall survival metastatic castration-resistant prostate cancer patients published in the Journal of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com